EurekAlert!

Promatix and Jasmin Fisher Lab at University College London accelerate hunt for oncology therapeutics with new algorithms for CipherPro

Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration with the laboratory of Professor Jasmin ...
WFMZ-TV

Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ...

Application of the integrated TxPro + CipherPro platform revealed a marked increase in predicted tumour-selective opportunities across multiple selection criteria. Using a DE threshold greater than 10 ...
PharmiWeb

ALSA Ventures Launches Promatix to Develop Next Generation Novel Oncology Therapeutics

LONDON--(BUSINESS WIRE)--ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of ...
WBOC

Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ...

Scarcity of truly tumour-selective targets remains a key limitation in ADC development, restricting delivery of safe and effective next-generation therapies Promatix’s integrated TxPro + CipherPro ...